Bronchiectasis – 2018 Pipeline Insight Report – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Bronchiectasis
– Pipeline Insight, 2018”
drug pipelines has been added to ResearchAndMarkets.com’s
offering.

This report offers a comprehensive insight of the pipeline (under
development) therapeutics scenario and growth prospects across
Bronchiectasis development.
The report provides detailed coverage of the pipeline landscape for this
mechanism of action, equipped with data from multiple sources with
complete pipeline analysis by developmental stage, associated
indications, route of administration and molecule type.

Scope

  • The report provides a snapshot of the pipeline development for
    Bronchiectasis
  • The report covers pipeline activity across the complete product
    development cycle i.e. clinical, pre-clinical and discovery stages for
    Bronchiectasis
  • The report provides pipeline product profiles which includes product
    description, developmental activities, licensors & collaborators and
    chemical information
  • Provides pipeline assessment by monotherapy and combination therapy
    products, stage of development, route of administration, and molecule
    type for Bronchiectasis
  • The report also covers the dormant and discontinued pipeline projects
    related to Bronchiectasis
Companies Featured

  • Alitair Pharmaceuticals Inc.
  • Bayer AG
  • Chiesi Farmaceutici SpA
  • GlaxoSmithKline PLC
  • Grifols SA
  • Insmed Inc.
  • Kamada Ltd.
  • Polyphor Ltd.
  • Recipharm AB
  • Vertex Pharmaceuticals Inc.
  • Novartis Pharmaceuticals
  • Regend Therapeutics
  • Zambon SpA

Key Topics Covered

1. Report Introduction

2. Bronchiectasis Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products for Bronchiectasis

4. Comparative Analysis

5. Products in Clinical Stage

5.1 Drug Name: Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

6. Products in Pre-Clinical and Discovery Stage

6.1 Drug Name: Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment

  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

8. Inactive Products

8.1 Drug Name: Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/7btzpg/bronchiectasis?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Respiratory
Drugs